Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Imricor Medical SystemsASX:IMR 45 Receivables Turnover is 0.38 as of Dec. 2025. GuruFocus rates ASX:IMR with a GF Score™ of 45/100 and a GF Value™ of A$0.10 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 812 Medical Devices & Instruments companies, Imricor Medical Systems ranks worse than 96.43% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Imricor Medical Systems's Revenue for the
six
months ended in Dec. 2025 was A$0.14 Mil. Imricor Medical Systems's average Accounts Receivable for the
six
months ended in Dec. 2025 was A$0.38 Mil.
Hence, Imricor Medical Systems's Receivables Turnover for the
six
months ended in Dec. 2025 was 0.38.
Imricor Medical Systems (ASX:IMR) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Imricor Medical Systems Receivables Turnover Related Terms
Imricor Medical Systems Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Imricor Medical Systems's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Imricor Medical Systems Receivables Turnover Chart
ASX:IMR vs ABT, SYK, MDT: Receivables Turnover Comparison
For the Medical Devices subindustry, Imricor Medical Systems's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Imricor Medical Systems Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Imricor Medical Systems's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Imricor Medical Systems's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Imricor Medical Systems (ASX:IMR) has a Receivables Turnover of 0.38 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Imricor Medical Systems and its competitors. According to the industry distribution chart, Imricor Medical Systems ranks #783 out of 812 companies in the Medical Devices & Instruments industry, placing it in the top 96.4%.
Is Imricor Medical Systems' Receivables Turnover too high?
Imricor Medical Systems' current Receivables Turnover is 0.38. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. Imricor Medical Systems' value of 0.38 is 93.1% below this industry median. Based on the distribution chart, Imricor Medical Systems ranks #783 out of 812 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Imricor Medical Systems has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Imricor Medical Systems' Receivables Turnover compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Imricor Medical Systems ranks #783 out of 812 companies for Receivables Turnover. This places Imricor Medical Systems in the lower half of its industry. The industry median Receivables Turnover is 5.51. Imricor Medical Systems' value of 0.38 is 93.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Imricor Medical Systems's current Receivables Turnover of 0.38 is 93.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Imricor Medical Systems and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Imricor Medical Systems's current Receivables Turnover is 0.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imricor Medical Systems stock overvalued right now?
Based on GuruFocus' analysis, Imricor Medical Systems (ASX:IMR) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.10, compared to a current price of A$1.67 — trading 1570% above its estimated fair value. The current Receivables Turnover is 0.38 and 93.1% below the Medical Devices & Instruments industry median of 5.51. Imricor Medical Systems' overall GF Score™ is 45/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Imricor Medical Systems (ASX:IMR), the current Receivables Turnover is 0.38 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Imricor Medical Systems (ASX:IMR) Overvalued in 2026?
Based on GuruFocus' analysis, Imricor Medical Systems stock appears to be overvalued.
The current stock price of A$1.67 is trading 1570% above its estimated GF Value™ of A$0.10.
GuruFocus considers Imricor Medical Systems to be Significantly Overvalued.
Key valuation signals for ASX:IMR:
Receivables Turnover: 0.38
GF Value™: A$0.10 vs. price of A$1.67 (1570% above fair value)
Industry Position: 93.1% below the Medical Devices & Instruments median (#783 of 812)
No single metric tells the full story. See the ASX:IMR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Imricor Medical Systems Inc is a medical device company that develops MRI-guided technology to address issues with traditional X-ray ablation procedures. Its principal business activities are designing, manufacturing, and selling MRI-compatible products for cardiac catheter ablation procedures to treat arrhythmias. The company's products include the Advantage-MR EP Recorder/Stimulator, Vision-MR Ablation Catheter, and Vision-MR Dispersive Electrode. Geographically, the company generates maximum revenue from Europe.
45GF Score
Get the complete analysis for ASX:IMR
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IMR has been successfully added to your 
